Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 50

Arthroscopic ACL reconstruction with peroneus longus graft with or without a platelet-rich plasma (PRP) injection

Official title: Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection: A Randomized Controlled Trial

Run by Lahore General Hospital · NCT07470359 · Data updated 2026-11-12

This test sees if a single 4 ml intra-articular PRP injection given during ACL reconstruction with a peroneus longus graft helps adults (18–50) with isolated ACL tears recover better over 12 months.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 50 Years
SexAll
Enrollment60 (estimated)
SponsorLahore General Hospital
Government
Locations1 site (Lahore, Punjab Province)
StatusRecruiting
StartedFebruary 20, 2026
Main results expectedAugust 31, 2027
Study endsNovember 30, 2027
Registry record updatedMarch 13, 2026
Trial IDNCT07470359 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–50 with a primary, complete isolated ACL tear planning arthroscopic reconstruction with a peroneus longus autograft who are active in sports or regular physical activity and can attend follow-up visits are ideal candidates.

Probably not a fit

Patients with prior surgery on the affected knee, multi-ligament injuries, significant cartilage damage or knee osteoarthritis, systemic inflammatory disease, bleeding disorders, current anticoagulant use, or recent intra-articular corticosteroid injection are excluded and unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, prospective randomized controlled Phase 2 trial in Lahore, Pakistan will randomize 88 adults with isolated complete ACL tears to receive either a single 4 ml intra-articular PRP injection or saline at the time of arthroscopic ACL reconstruction with a peroneus longus autograft. PRP is prepared from 15–20 ml venous blood using a single-spin centrifugation (3500 rpm) and delivered as 2 ml per femoral/tibial tunnel during surgery. Functional recovery will be measured using KOOS4 questionnaires at baseline, 3, 6, and 12 months with primary comparisons made by ANCOVA adjusting for baseline scores. The trial is designed to be feasible in a resource-limited setting and integrates follow-up into routine clinic visits to minimize dropout.

Why it matters

Potential benefit: If successful, adding a single PRP injection could improve knee function and speed recovery after ACL reconstruction with peroneus longus grafts while remaining affordable for resource-limited settings.

How similar studies have gone: Prior ACL reconstruction studies of PRP have reported mixed results with some signs of improved graft healing and function, but findings are inconsistent and PRP use specifically with peroneus longus autografts is not well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria: Age between 18 and 50 years. Diagnosis of a primary, complete ACL tear requiring reconstruction. Willingness to undergo arthroscopic ACL reconstruction with peroneus longus autograft.

Active individuals participating in sports or regular physical activity. Willingness to provide informed consent and adhere to the study protocol, including follow-up visits and rehabilitation.

Ability to understand and complete study questionnaires. - Exclusion Criteria: Previous knee surgery on the affected limb. Concomitant ligamentous injuries requiring additional reconstruction (e.g., PCL, MCL, LCL Grade III).

Significant chondral damage (Outerbridge grade \> 2 on pre-operative MRI or intra-operative assessment).

Pre-existing knee osteoarthritis (Kellgren-Lawrence grade \> 2). Systemic inflammatory conditions (e.g., rheumatoid arthritis). Bleeding disorders or coagulopathies. Current use of anticoagulants. Corticosteroid injection into the knee within 6 weeks prior to surgery. Pregnancy or lactation. Inability to comply with the rehabilitation protocol. Infection or history of infection in the affected knee. History of previous contralateral ACL injury (to isolate primary injury outcomes).

\-

Where it's running

  • Lahore General Hospital
    Lahore, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.